Most Read Articles
Jairia Dela Cruz, 12 Dec 2019
Use of isatuximab (Isa) in combination with pomalidomide and dexamethasone (PomDex) appears to lead to more favourable outcomes in elderly patients with relapsed/refractory multiple myeloma (RRMM) as compared with PomDex alone, according to the results of a subgroup analysis of the ICARIA-MM trial presented at the 61st Annual Meeting of the American Society of Hematology (ASH 2019).
Rachel Soon, 2 days ago

Pharmaceutical industry representatives highlighted lesser-known career opportunities for licensed pharmacists at the recent Pharmaceutical Industries Pharmacists Insights 3.0 (PIPI 3.0) symposium in Petaling Jaya.

Pearl Toh, 13 Oct 2018
An observational study reveals that many hypertensive women stop taking their antihypertensive medications during pregnancy, although it was unclear whether it was appropriate to do so.
Rachel Soon, Yesterday

Lim Jack Shen, assistant general manager of business development at Berjaya Corporation, talks about his experiences with developing MyTigas Alliance, a collaboration of independent community pharmacies for providing group healthcare services.

Memantine of no benefit in glaucoma treatment

13 Sep 2018

Long-term treatment with memantine is well tolerated but does not effectively prevent glaucomatous progression in patients with open-angle glaucoma (OAG), according to the results of two phase III trials.

The overall population comprised 2,298 bilateral OAG patients with glaucomatous optic disc damage and visual field loss in one eye, intraocular pressure (IOP) 21 mm Hg, and high-risk of progression. The two trials followed the same protocol, wherein patients were randomized to receive memantine 20 mg (n=974) or 10 mg (n=664) or placebo (n=660) tablets daily for 48 months.

The predefined primary efficacy measure was glaucomatous visual field progression, as assessed using full-threshold standard automated perimetry (SAP). Other efficacy measures were glaucomatous progression of visual field (measured using frequency doubling technology [FDT]) and optic nerve damage (evaluated using stereoscopic optic disc photographs). Safety evaluations included adverse events (AEs), best-corrected visual acuity (BVCA), biomicroscopy, IOP and ophthalmoscopy.

Compared with placebo, use of memantine for 48 months did not delay glaucomatous progression significantly in the individual studies and pooled analyses. The pooled risk reduction ratio for SAP-assessed progression was −0.13 (95 percent CI, −0.40 to 0.09) with the 10-mg dose and −0.17 (−0.46 to 0.07) with the 20-mg dose. Similar results were obtained per FDT and stereoscopic optic disc photographs.

Memantine was well tolerated, and dizziness was the most frequently reported AE. Changes in biomicroscopy and ophthalmoscopy findings with ≥1 severity grade increase, BVCA, mean IOP, and average central corneal thickness were comparable among the three treatment groups.

An uncompetitive N-methyl-D-aspartate (NMDA) receptor antagonist, memantine is currently approved in several countries for the treatment of moderate to severe Alzheimer’s and Parkinson’s diseases. The drug can inhibit overstimulation of the NMDA receptor and potentially provide neuroprotection by preventing excessive calcium influx, the investigators said.

However, pooled results of visual field and optic disc analyses from the two trials revealed no consistent or beneficial effects of memantine in OAG based on ophthalmic assessments from the two trials, they added.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Pharmacist - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Jairia Dela Cruz, 12 Dec 2019
Use of isatuximab (Isa) in combination with pomalidomide and dexamethasone (PomDex) appears to lead to more favourable outcomes in elderly patients with relapsed/refractory multiple myeloma (RRMM) as compared with PomDex alone, according to the results of a subgroup analysis of the ICARIA-MM trial presented at the 61st Annual Meeting of the American Society of Hematology (ASH 2019).
Rachel Soon, 2 days ago

Pharmaceutical industry representatives highlighted lesser-known career opportunities for licensed pharmacists at the recent Pharmaceutical Industries Pharmacists Insights 3.0 (PIPI 3.0) symposium in Petaling Jaya.

Pearl Toh, 13 Oct 2018
An observational study reveals that many hypertensive women stop taking their antihypertensive medications during pregnancy, although it was unclear whether it was appropriate to do so.
Rachel Soon, Yesterday

Lim Jack Shen, assistant general manager of business development at Berjaya Corporation, talks about his experiences with developing MyTigas Alliance, a collaboration of independent community pharmacies for providing group healthcare services.